Skip to main content
Clinical Trials/NCT04531670
NCT04531670
Completed
N/A

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

University of Connecticut1 site in 1 country50 target enrollmentJuly 26, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV Prevention Program
Sponsor
University of Connecticut
Enrollment
50
Locations
1
Primary Endpoint
Feasibility - participants retained
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).

Detailed Description

A Hybrid type 1 implementation science design,will be used to pilot test the APN-led iRaPID program while exploring information on its implementation at multiple time points through the study. The hybrid type 1 pilot trial provides an implementation heuristic to assess potential research questions, perhaps more comprehensively, accurately and certainly earlier than could be achieved in a sequential 'intervention-then-preliminary-pilot study' strategy. In this hybrid type 1 pilot trial, the RCT will be utilized to: * Examine feasibility and acceptability among PWID and clinical stakeholders for an adapted APN-delivered, rapid HIV prevention program for PWID (iRaPID) that integrates same-day PrEP and OAT. * Estimate the preliminary efficacy of PrEP and OAT uptake in a pilot randomized controlled trial of the iRaPID vs. treatment as usual strategy in PWID without HIV. To assess future scale-up factors, the Consolidated Framework for Implementation Research (CFIR) will be utilized with the nominal group technique (NGT). It is a conceptual framework developed to guide the assessment of multilevel implementation contexts. The CFIR framework was selected because it provides a structured menu of constructs associated with effective implementation. It consists of 5 domains with 39 underlying constructs. As recommended by Damschroder, in this study 8 CFIR constructs based on the relevancy will be measured. During the NGT, participants will be asked questions related to the multi-level implementation factors that will be based on the sample guide available on http://cfirguide.org but tailored for PWID. After posing each question, participants silently generate individual ideas. Then, using a round-robin elicitation process, each person contributes ideas that are recorded visually. They then engage in group discussion to clarify and evaluate the ideas. Items are then grouped by consensus with duplicate items removed. Then, each participant casts three votes on items as they deem them important. Votes are immediately tallied, ranked based on total number of votes, and the facilitator leads a final discussion to review the results. Sessions will take 60 minutes and be audio-recorded and transcribed.

Registry
clinicaltrials.gov
Start Date
July 26, 2021
End Date
February 28, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Roman Shrestha

Assistant Professor

University of Connecticut

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years
  • HIV-negative
  • Reporting injection drug use (past 3 months)
  • Substantial ongoing risk for HIV acquisition
  • OUD based on the DSM-V criteria
  • Stakeholders
  • Age ≥18 years
  • APNs, patient navigators, counselors, and administrators who reflect the range of characteristics of staff members that are involved in HIV care to PWID

Exclusion Criteria

  • PWID and stakeholders
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Unable to provide informed consent
  • Unable to read and understand English

Outcomes

Primary Outcomes

Feasibility - participants retained

Time Frame: 6 months

The number of participants retained will be used as a measurement of feasibility

Feasibility - participants screened

Time Frame: 6 months

The number of participants screened will be used as a measure of feasibility

Feasibility - participants randomized

Time Frame: 6 months

The number of participants randomized will be used as a measurement of feasibility

Feasibility - participants recruited

Time Frame: 6 months

The number of participants recruited will be used as a measurement of feasibility

Feasibility - treatment adherence

Time Frame: 6 months

The number of participants that adhere to treatment will be used as a measurement of feasibility

Acceptability

Time Frame: 6 months

Acceptability will be measured using a 10-item acceptability rating profile. Acceptability will be based on descriptive statistics from the acceptability measures (score ≥70) and analysis of qualitative data, which will be done using thematic analysis

Uptake of PrEP and OAT

Time Frame: 6 month

PrEP uptake proportion at 6-month follow-up will be estimated and compared using linear contrast statement in SAS.

Adherence to PrEP

Time Frame: 6 months

Adherence to PrEP will be measured using the visual analogue scale and dried blood spots

Persistence on PrEP

Time Frame: 6 months

Persistence on PrEP will be measured by collecting information on refilled within 30 days after exhausting PrEP from previous fill data

Study Sites (1)

Loading locations...

Similar Trials